InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,728.80
(
0.41%
)
US TECH 100
19,528.00
(
0.90%
)
Dow Jones
42,052.19
(
0.69%
)
Brent Oil
72.91
(
0.00%
)
Bitcoin
69,425.50
(
-0.08%
)
Post# of 253509
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 839
Posts 120657
Boards Moderated 13
Alias Born 09/05/2002

DewDiligence

Member Level

Re: ThomasS post# 76241

Monday, 04/20/2009 2:34:21 PM

Monday, April 20, 2009 2:34:21 PM

Post# of 253509
MNTA – Please see #msg-37030489 for the rationale of the M402 cancer program.

If FoB-enabling legislation were to flounder in Congress, I could see a step-up in R&D for M402, and MNTA’s small capital raise in December could end up looking smart. (Of course, MNTA will be rolling in dough in the FDA comes through with a single-company approval of generic Lovenox.)


“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up